Introduction: High-dose radiotherapy to the hemithorax for patients with malignant pleural mesothelioma is a controversial treatment. Between 2003 and 2013 our institution had a policy of giving hemithoracic radiotherapy to at least 45 Gy. This retrospective study reports survival, progression and toxicity associated with this policy. Methods: Seventy-one patients with pleural mesothelioma were irradiated with doses of 45-60 Gy. Conformal radiotherapy (3D-CRT) to the lower hemithorax was used for 17 and intensity-modulated radiotherapy (IMRT) to the whole hemithorax for 54 patients. All patients have been followed up for at least 2 years from commencement of radiotherapy. Results: Sixty-four patients (90%) completed planned radiotherapy and seven stopped early, usually due to progressive disease. Median overall survival was 9.5 months (95% CI: 7.7-12.4) and median progression-free survival was 4.9 months (95% CI: 4.4-5.8). Eighty-seven per cent of patients progressed or died within 2 years: 25% in-field, 49% outside the RT field and 13% died without progression. Severe toxicity (grade 3-5) was observed in 53% of 3D-CRT and 78% of IMRT patients, most commonly pulmonary fibrosis 27%, radiation dermatitis 18%, dyspnoea 11%, GGT increased 11%, pneumonitis 10%, pleuritic pain 8% and fatigue 8%. There were two, possibly three, treatmentrelated deaths. Conclusion: High-dose radiotherapy to the hemithorax caused significant toxicity to most patients with no improvement in survival. Lower doses of radiotherapy to limited volumes may be useful for palliative purposes.
Introduction
The optimal management of malignant pleural mesothelioma is controversial, principally because it is a rare malignancy with few randomised trials to guide therapy. Australia has one of the world's highest incidences of this disease due to the widespread use of asbestos products, with about 700 cases diagnosed annually. 1 The survival rate has changed little since the 1970s with median survival from diagnosis of 9 months, and very rare longterm survivors. [2] [3] [4] Radical surgery for mesothelioma has high rates of severe side effects and local relapse, with many institutions abandoning extrapleural pneumonectomy in favour of less morbid pleurectomy/decortications or even more palliative procedures. 5 Chemotherapy produces modest benefits with few durable responses. 6 Use of radiotherapy alone with a curative intent for unresectable disease has traditionally been considered impractical as the target volumes would typically exceed normal tissue tolerance limits. 7, 8 Prior to 3-dimensional conformal radiotherapy, doses of 50 Gy alone were associated with a treatment-related mortality rate of at least 16% and no improvement in survival. 9 It has been shown in retrospective studies that doses greater than 40 Gy improve local control but are limited by dose constraints for the remaining lung tissue.
Nevertheless, there are reports of high-dose radiotherapy after pneumonectomy and pleurectomy/decortication, which are used to argue for an aggressive approach. 12 Intensity-modulated radiation therapy (IMRT) was originally developed for small tumours with limited motion, and then adapted to the large surgical bed for malignant pleural mesothelioma by investigators at the MD Anderson Cancer Center. 13, 14 The goal of developing IMRT technique is to improve the therapeutic ratio of giving a higher dose to areas at risk while sparing the normal abutting structures. An IMRT technique generally results in a more heterogeneous dose distribution, with a larger volume of normal tissue receiving low-dose radiation than standard two-and three-dimensional techniques. Several studies have shown improved toxicity profiles and local control with IMRT after pleurectomy/ decortication. [15] [16] [17] In addition, helical tomotherapy, a form of IMRT that uses a rotational gantry system, has also shown promise in the adjuvant treatment of pleural mesothelioma in terms of improved local control with acceptable toxicity reported.
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In 2003, our institution commenced a programme that offered highly conformal high-dose radiotherapy for treatment of mesothelioma patients who were not candidates for radical surgery. Three-dimensional conformal radiotherapy (3D-CRT) was initially utilised followed by intensity-modulated radiotherapy (IMRT). Functional imaging with 18 F-FDG PET scans was also used consistently. Feigen et al. published the results of the first 14 treated patients in 2011. 19 It was believed that toxicities from radiation damage to normal tissues surrounding the cancer deposits could be limited by new radiotherapy techniques (3D-CRT and IMRT). The aim of this study is to present the long-term survival and toxicity outcomes of highly conformal high-dose radiotherapy for malignant pleural mesothelioma at our institution.
Methods
All patients gave written consent at our institution for the radiation treatment. This retrospective analysis was approved by our institutional human ethics committee in August 2014. All patients with histologically confirmed pleural mesothelioma treated at our institution with planned doses of at least 45 Gy were reviewed for this study. They were all staged clinically with 18 F-FDG PET/ CT scans following the International Mesothelioma Interest Group Staging System. 20 Of the 74 patients who met these inclusion criteria, three with prior extrapleural pneumonectomy were excluded from this analysis. The remaining 71 patients commenced radiotherapy between 31 July 2003 and 15 July 2013.
The most common pattern of early recurrence is deep in the costophrenic recess, most often from inadequate resection of mesothelioma: hence the rationale for this volume being treated post-operatively with radiotherapy.
The programme began in July 2003 using 3D-CRT, targeting areas of high FDG-avidity located in the hemithorax. In April 2006 the first patient was treated with intensity-modulated radiotherapy (IMRT), when it became available at our centre, and this became standard practice from January 2009. With the introduction of IMRT the target volume was increased to encompass the entire hemithorax as it had been noted that the unirradiated portion of the affected hemithorax was the main site of disease failure in the earlier patients. Altogether 17 patients were treated with 3D-CRT and 54 with IMRT.
In the 3D-CRT cases the gross tumour volume within the hemithorax was contoured with a 1-2-cm margin, and in the IMRT cases the full hemithorax, including the full hemi-diaphragm and chest wall, was irradiated using the PET scan to define FDG-avid masses for boost doses. All patients underwent a course of megavoltage radiotherapy of 45-60 Gy in 1.8-2.4 Gy fractions over 6 weeks. The planned target volume (PTV) was generally prescribed 50.4-54 Gy and sites of high-18 F-FDG avidity received simultaneous integrated boosts of 6-10 Gy over the treatment course. Dosimetry parameters were calculated at the time of planning and re-calculated retrospectively for this study for all patients and compared to dose constraints specified for liver, oesophagus, thecal sac, heart, contralateral lung and contralateral kidney.
Patients were followed up with clinical assessments and CT scans and those who were geographically accessible had repeat PET/CT scans. Serum mesothelin levels were repeated if they were elevated at presentation. Toxicities were recorded by the treating radiation oncologist and others, and reviewed and graded according to the NCI Common Toxicity Criteria 4.0 retrospectively by one of two senior radiation oncologists (MW, FF). 21 Toxicities based on laboratory tests were graded only for the first 6 months after ceasing treatment: subsequent tests were considered more likely to reflect progression of disease or subsequent chemotherapy rather than radiotherapy. Data were entered into a database and thoroughly checked by an experienced data manager (FP). All patients were followed up to death or the close-out date (12 March 2015), whichever was earlier. Overall and progression-free survival from commencement of radiotherapy was estimated using the Kaplan-Meier method, with censoring of times at the close-out date. 22 For overall survival the events counted were deaths from any cause. For progression-free survival, the events counted were the first progression of mesothelioma at any site or death without progression. The Brookmeyer-Crowley method was used to obtain 95% confidence intervals (CI) for median survival times and the logit transformation was used to obtain 95% CIs for percentages surviving at 1 and 2 years. Subgroups were compared using the Mantel-Cox log rank test. The cumulative incidences of in-field progression, out-of-field progression and death without progression were estimated from the progression-free survival curve using the method of Kalbfleisch and Prentice. 23 Simultaneous in-field and out-of-field progressions, as well as progressions at unknown site, were counted as in-field progressions in the cumulative incidence curve. The median follow-up time was estimated using the reverse Kaplan-Meier method, in which deaths are censored and being alive at the close-out date is counted as the event. The worst grades of each toxicity were calculated and the crude incidences were reported. Actuarial estimates of toxicity incidences (i.e. cumulative incidence from a competing risks analysis of toxicity and death) were not indicated due to the completeness of follow-up.
Comparisons of continuous variables between the two RT techniques were done using the Wilcoxon rank sum test. 24 
Results
Fifty-six patients (79%) were male and the median age at commencement of radiotherapy was 64 years (range 45-81). Patient and tumour characteristics prior to commencing radiotherapy are summarised in Table 1 . There were no stage I cases and 83% had advanced stage III-IV disease. Time from diagnosis to commencement of radiotherapy ranged from 2 to 69 months (median 9 months) and was significantly longer for the IMRT patients (3D-CRT median 6.2 months, IMRT median 11.1 months, P = 0.0001). This was probably because 87% of the 54 IMRT patients had received prior chemotherapy compared to only 24% of the 17 3D-CRT patients. Altogether 51 patients (72%) received prior chemotherapy (usually pemetrexed with either cisplatin or carboplatin), 38 (54%) debulking surgery (pleurectomy/decortication) and 35 (49%) pleurodesis. One patient had prior radiotherapy to the chest wall (21 Gy in three fractions using electrons) to prevent port site recurrence. Most patients had good performance status (ECOG 0-1) but eight were ECOG grade 2 and two were ECOG 3 prior to radiotherapy. Pre-radiotherapy tests showed that 27 patients (38%) had abnormal haematological function, mainly grade 1-2 anaemia, 24 (34%) had abnormal liver function (ALP, ALT or GGT grade 1-3) and 7 (10%) had abnormal renal function (creatinine grade 1-2), probably due to their disease or prior chemotherapy. Soluble mesothelin-related peptides within 3 months prior to radiotherapy were recorded for 43 patients (61%). Of these, 18 were within the normal range (≤1.5 gmol/L) and 25 were above normal (range 1.6-170 gmol/L).
Radiotherapy
Seventeen patients were treated with 3D-CRT and 54 patients received IMRT. Patients were planned to receive doses of megavoltage radiotherapy ranging from 45 to 60 Gy over 6 weeks, all as outpatients. The prescribed dose, including concomitant boost, was significantly higher for IMRT than for the 3D-CRT patients (3D-CRT median 50.4, range 45-60 Gy; IMRT median 60, range 54-60 Gy, P < 0.0001). The PTV was also significantly larger for the IMRT patients (median 6.5 L, range 2.4-9.6 L) than for the 3D-CRT patients (median 2.9 L, range 1.4-6.3 L) (P < 0.0001). In some cases the PTV did not encompass all disease sites because of dose constraints for normal tissue. Despite this, planned doses to the liver, oesophagus, thecal sac, heart, contralateral lung and contralateral kidney exceeded pre-specified dose constraints in 13%, 6%, 6%, 72%, 13% and 1% of cases respectively (Table 2) .
Seven patients (one 3D-CRT, six IMRT) did not complete their treatment, six due to progressive disease and one chose to miss the last fraction. Five patients (one 3D-CRT, four IMRT) had treatment breaks of more than 3 days: two due to toxicity, two due to machine maintenance or public holidays and one for replanning after the first fraction. Four 3D-CRT patients and 1 IMRT (7%) had subsequent courses of palliative radiotherapy to the chest for recurrence, 25 (35%) had subsequent pleurodesis and 27 (38%) subsequent chemotherapy.
Treatment outcomes
Eight patients remained alive at the close-out date, including four without progression. Follow-up time for living patients was at least 25 months (median 48 months). One patient has survived 10.2 years but the survival graphs were curtailed at 5 years in order to show more detail in the early years. Of the 63 deaths, 51 were due to mesothelioma (one complicated with possibly RT-related myelitis), 2 due to radiation pneumonitis, 1 due to another cancer (melanoma), 3 due to other causes (two stroke, one pulmonary embolus) and 6 unknown (probably mesothelioma). Estimated overall median survival time was 9.5 months, with 42% surviving at 1 year and 18% at 2 years (Table 3 , Fig. 1 ). The survival of patients treated with 3D-CRT was similar to that of the IMRT patients. As expected, patients with good pre-treatment performance status (ECOG 0-1) survived longer than those with ECOG 2-3 performance status (median 11.1 months versus 4.9 months, P = 0.021).
Nine patients (13%) first progressed in the radiotherapy field, 37 (52%) outside the field, 10 (14%) both in and outside simultaneously and 2 (3%) with the sites not specified. Nine patients (13%) died without documented progression. Median progression-free survival time was estimated to be 4.9 months for the whole group and 4.4 and 5.4 months for the 3D-CRT and IMRT patients respectively (Table 3) . At 2 years following commencement of radiotherapy the cumulative incidence graph showed that 25% of patients (SE 5.2%) had first progressed in the RT field (including concurrent and nonspecific progressions), 49% (SE 5.9%) outside the field and 13% had died without progression being recorded (SE 3.9%) (Fig. 2) . The remaining 13% were alive without progression at 2 years (Table 3) .
Toxicities
Severe toxicity (grade 3-5) was observed in nine 3D-CRT patients (53%, CI 28-77%) and 42 IMRT patients (78%, CI 64-88%). The most common severe toxicities were pulmonary fibrosis in 27% of patients, radiation dermatitis 18%, dyspnoea 11%, GGT increased 11%, pneumonitis 10%, pleuritic pain 8% and fatigue 8%. There were two, possibly three, treatment-related deaths -two radiation pneumonitis and one patient with myelitis which was possibly related to radiotherapy, although the cause of death was given as malignant mesothelioma. Table 4 shows the crude incidences of worst grades of all toxicities which occurred in two or more cases. There were also single cases of grade 5 myelitis (possibly RT related), grade 4 sepsis, grade 3 enteritis and atrial fibrillation, grade 2 cellulitis, pneumonia, odynophagia, oral thrush, shoulder pain and skin infection, and grade 1 oesophageal stricture, pericarditis, hypotension, 14 ‡Worst grade of laboratory tests within 6 months of ceasing radiotherapy.
§Worst grade at any time after commencing radiotherapy. diarrhoea and dyspepsia. No patients had brachial plexopathy, restrictive cardiomyopathy, hepatic necrosis or contralateral pulmonary fibrosis.
Discussion
In this retrospective study of patients treated with highdose palliative radiotherapy at our institution between 2003 and 2013 we estimated median overall survival from the commencement of radiotherapy to be 9.5 months with 18% surviving at 2 years, and median progression-free survival to be 4.9 months with 13% surviving without progression at 2 years. Within the first 2 years the sites of first progression were in the radiotherapy field in 25% of patients, outside the field in 49%, and 13% died without progression. Severe toxicity (grade 3 or worse) was experienced by 72% of patients, with two, possibly three, treatment-related deaths.
Patients were offered high-dose radiotherapy because they had advanced disease or had already progressed after chemotherapy or surgery. Their options were limited. Of the 71 patients irradiated, 13 survived more than 2 years and 1 more than 10 years after commencing RT. The patient who survived more than 10 years had stage II epithelioid mesothelioma and was ECOG 0 before commencing radiotherapy. He was treated with 50.4 Gy 3D-CRT and progressed more than 4 years later. He had subsequent chemotherapy and a second course of palliative radiotherapy of 50 Gy to the ipsilateral chest avoiding overlap and at the close-out date his recurrent disease was progressing very slowly.
Radiotherapy has a role for palliative management of patients with mesothelioma, with studies showing effective palliation is associated with doses ≥40 Gy, although lower doses have also been found to be effective. 25, 26 However, most studies have had small numbers, have used outdated radiotherapy techniques, and measures of control were not standardised. Although the patients in our cohort were not formally assessed for palliative response, most of them did not have a symptomatic benefit from the radiotherapy.
The previous paper from our institution by Feigen et al. reported on 14 patients with follow-up PET scans who had median survival of 17 months from commencement of radiotherapy. However, seven patients, who did not receive PET scans after treatment, were excluded, which would largely explain the apparently better survival. 19 In addition, the Kaplan-Meier method of survival analysis was not used in that analysis. Abstracts on various subgroups have been published in conference proceedings but these predated a rigorous review of the toxicities and thus presented a more optimistic picture than was revealed by the full analysis of all patients in this paper. 27, 28 The presence of intact lung after pleurectomy/decortication presents concerns about pulmonary toxicity and previous studies using radiotherapy techniques other than IMRT have shown treatment-related deaths. 10 The assumption of the technique used at our institution was that loss of ventilation in the irradiated lung could be largely compensated by the functioning contralateral lung, but the other toxicities outweighed the potential benefits of this treatment. There are other series using IMRT and tomotherapy that have reported lower rates of toxicities than what we have found, however, most are single institution retrospective studies with fewer patients than our series. 15, 17, 18, [29] [30] [31] The higher incidence of severe toxicity in our IMRT patients (78%), compared to other series and to our 3D-CRT patients (53%), may be due to the larger target volumes and higher doses used for the IMRT group. Based on our findings, we have now ceased treating patients with this specific technique for malignant pleural mesothelioma.
